Aztreonam

Absorption	Less than 1% absorbed from the gastrointestinal tract following oral administration. Completely absorbed following intramuscular administration.
Volume of distribution	12.6 L
Protein binding	Serum protein binding averaged 56% and is independent of dose. Impaired renal function, 36 to 43%.
Metabolism	Approximately 6 to 16% metabolized to inactive metabolites by hydrolysis of the beta-lactam bond, resulting in an open-ring compound.
Route of elimination	In healthy subjects, aztreonam is excreted in the urine about equally by active tubular secretion and glomerular filtration. Urinary excretion of a single parenteral dose was essentially complete by 12 hours after injection.
Half life	The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).
Clearance	91 mL/min [healthy]
Toxicity	Not Available
Affected organisms	Enteric bacteria and other eubacteria